Capreomycin sulfate: Difference between revisions
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | __NOTOC__ | ||
{{Capreomycin sulfate}} | |||
{{CMG}} ; {{AE}}; {{chetan}} | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=808e4421-2b9c-41e1-a82c-39256b112ae8 | publisher = | date = | accessdate = 24 December 2013 }}</ref> | |||
==References== | |||
{{Reflist}} | |||
{{FDA}} | |||
[[Category:Antibiotics]] | |||
[[Category:Wikinfect]]==Overview== | |||
==Category== | ==Category== | ||
Revision as of 21:55, 24 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] ; Associate Editor(s)-in-Chief: ; Chetan Lokhande, M.B.B.S [3]
References
- ↑ "CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN]". Retrieved 24 December 2013.
Adapted from the FDA Package Insert.==Overview==
Category
US Brand Names
CAPASTAT SULFATE®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages